Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11010-022-04376-6.pdf
Reference123 articles.
1. Frazer R, Irvine AE, McMullin MF (2007) Chronic myeloid leukaemia in the 21st century. Ulster Med J 76:8–17
2. Sattlermc M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40:4–10. https://doi.org/10.1053/shem.2003.50034
3. Iqbal N, Iqbal N (2014) Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. https://doi.org/10.1155/2014/357027
4. Sherbenou DW, Hantschel O, Kaupe I et al (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116(17):3278–3285. https://doi.org/10.1182/blood-2008-10-183665
5. Rosenzweig SA (2018) Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 138:71–98
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in the Treatment of Chronic Myeloid Leukemia;Recent Patents on Anti-Cancer Drug Discovery;2024-02
2. Clinical pharmacokinetics and Drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: a clinical perspective;Critical Reviews in Oncology/Hematology;2024-02
3. Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low‐dose dasatinib;Geriatrics & Gerontology International;2023-11-03
4. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26
5. Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases;Toxicology in Vitro;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3